Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Respir Res ; 24(1): 152, 2023 Jun 09.
Artigo em Inglês | MEDLINE | ID: mdl-37296478

RESUMO

COVID-19-related acute respiratory distress syndrome (CARDS) is associated with high mortality rates. We still have limited knowledge of the complex alterations developing in the lung microenvironment. The goal of the present study was to comprehensively analyze the cellular components, inflammatory signature, and respiratory pathogens in bronchoalveolar lavage (BAL) of CARDS patients (16) in comparison to those of other invasively mechanically ventilated patients (24). In CARDS patients, BAL analysis revealed: SARS-CoV-2 infection frequently associated with other respiratory pathogens, significantly higher neutrophil granulocyte percentage, remarkably low interferon-gamma expression, and high levels of interleukins (IL)-1ß and IL-9. The most important predictive variables for worse outcomes were age, IL-18 expression, and BAL neutrophilia. To the best of our knowledge, this is the first study that was able to identify, through a comprehensive analysis of BAL, several aspects relevant to the complex pathophysiology of CARDS.


Assuntos
COVID-19 , Pneumonia , Síndrome do Desconforto Respiratório , Humanos , Estudos Prospectivos , Líquido da Lavagem Broncoalveolar , COVID-19/diagnóstico , SARS-CoV-2 , Lavagem Broncoalveolar , Síndrome do Desconforto Respiratório/diagnóstico , Síndrome do Desconforto Respiratório/metabolismo
2.
BMC Vet Res ; 12: 52, 2016 Mar 12.
Artigo em Inglês | MEDLINE | ID: mdl-26968657

RESUMO

BACKGROUND: The role of wild birds in the transmission and spread of mycoplasmas is not clear. Up to now different Mycoplasma species have been isolated from wild birds many of which are not considered pathogens sensu stricto for domestic flocks. This report describes the first isolation of Mycoplasma synoviae in a captive lesser flamingo (Phoeniconaias minor) held in a zoo in Italy and the laboratory investigations performed to elucidate its origin. Results showed that the strain was similar to the MS-H vaccine strain using the vlhA methods although no vaccination with this product was used in the zoo. CASE PRESENTATION: This paper describes investigations into a case in which 10 of 12 adult lesser flamingos (Phoeniconaias minor) died after having recently been moved from the Netherlands to a new zoo in Northern Italy. While most of the birds appeared to have died from the stress of movement and poor adaptation to their new environment, Mycoplasma synoviae, an important poultry pathogen in the layer and meat industry, was isolated for the first time from the trachea of one animal presenting catarrhal tracheitis and fibrinous airsacculitis. Genetic analysis of the conserved region of the vlhA was not able to differentiate the flamingo strain from the MS-H vaccine strain. However differences in the sequences of the obg gene of the flamingo and vaccine strain were detected. A test for temperature-sensitivity (ts) gave a ts (-) phenotype for the flamingo strain, in contrast to the ts (+) status of the MS-H strain. Based on this information and knowing that the flamingos were not vaccinated against M. synoviae, it is highly likely that the flamingo was infected with a genetically similar wild strain by contact with infected birds. CONCLUSIONS: This case provides evidence for the potential role of international trade of ornamental birds as a possible route of introduction of new mycoplasma strains between countries, and moreover highlight that vlhA gene sequencing was not sufficient to discriminate the wild strain isolated from the flamingo from the MS-H vaccine strain.


Assuntos
Animais de Zoológico/microbiologia , Doenças das Aves/microbiologia , Infecções por Mycoplasma/veterinária , Mycoplasma synoviae/fisiologia , Animais , Proteínas de Bactérias/genética , Doenças das Aves/diagnóstico , Doenças das Aves/patologia , Aves , Evolução Fatal , Proteínas de Ligação ao GTP/genética , Itália , Lectinas/genética , Tipagem Molecular , Infecções por Mycoplasma/diagnóstico , Infecções por Mycoplasma/microbiologia , Infecções por Mycoplasma/patologia , Mycoplasma synoviae/classificação , Mycoplasma synoviae/genética , Mycoplasma synoviae/isolamento & purificação , Países Baixos , Filogenia , Estresse Fisiológico , Temperatura , Traqueia/microbiologia
4.
Int J Infect Dis ; 92: 81-88, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31935535

RESUMO

OBJECTIVES: We present an updated picture (1/1/2017-31/08/2019) of the frequency of carbapenemase producing Klebsiella pneumoniae (CPKP) in surveillance rectal swabs (SRS) and in clinical samples (CS) of patients admitted to a tertiary level hospital, focusing on longitudinal evolution of CPKP detected in SRS and on colistin resistant strains. METHODS: Retrospective longitudinal analysis. Only the first positive CPKP strain isolated from each patient was included. RESULTS: 638 CPKP strains were identified (471 in SRS and 167 in CS). SRS frequency increased over time in the medical department, remained high in the surgical department (SD) and decreased in the intensive care department. Most SRS-71.3%-and 49.1% of CS had nosocomial origin; about half of the SRS were identified in the SD. Regarding SRS evolution, carriage was confirmed in 39.5% of patients, no more testing in 25.5%, clinical involvement in 24.8 %, and negative result in 10.2%. Rates of colistin resistance were 20.1% in 2017, 31.2% in 2018 and 26.9% in 2019. CONCLUSIONS: CPKP diffusion is still an important issue despite the surveillance program. It is vital to enhance medical staff's awareness on this because most CPKP first detections in SRS occurred during hospital stay due to a nosocomial acquisition with a comparable picture over time. Colistin resistance is increasing.


Assuntos
Proteínas de Bactérias/metabolismo , Infecção Hospitalar/microbiologia , Hospitais de Ensino , Infecções por Klebsiella/transmissão , Klebsiella pneumoniae/metabolismo , Centros de Atenção Terciária , beta-Lactamases/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/farmacologia , Colistina/farmacologia , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/transmissão , Farmacorresistência Bacteriana , Monitoramento Epidemiológico , Feminino , Humanos , Itália/epidemiologia , Infecções por Klebsiella/epidemiologia , Klebsiella pneumoniae/efeitos dos fármacos , Klebsiella pneumoniae/isolamento & purificação , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Reto/microbiologia , Estudos Retrospectivos
5.
J Pediatr (Rio J) ; 83(5 Suppl): S137-45, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18038019

RESUMO

OBJECTIVE: Vasopressin is a neuropeptide hormone which has been used clinically for more than 50 years and plays a major role in circulatory homeostasis and in the regulation of serum osmolality. Recent work has emphasized its role in the treatment of septic shock. This paper reviews the physiology of this neurohormone and the available evidence in favor of its use as a vasodilator for children in shock. SOURCES: MEDLINE, using the terms vasopressin, vasodilation, shock and septic shock, plus synonyms and related terms. Classic publications on the topic were also reviewed and selected depending on their relevance to the study objectives. SUMMARY OF THE FINDINGS: Vasopressin is synthesized in the neurohypophysis and released in response to a decrease in plasma volume or an increase in serum osmolality. The action of vasopressin is mediated by the activation of oxytocin receptors and of several G protein-coupled receptors, which are classified according to their location and intracellular transmission routes as V1 receptors (or V1b), V2 and V3 receptors (or V1b). The main role of vasopressin is to induce vasoconstriction. However, in certain organs, it can also induce selective vasodilation. Several clinical studies in adults and children have reported that the effects of vasopressin for the treatment of vasodilatory septic shock, due to a variety of causes, are both beneficial and safe. CONCLUSIONS: The evidence is restricted. Most studies are retrospective and include a small number of patients. Nevertheless, there is significant experience concerning the use of vasopressin in Pediatrics. Vasopressin has a beneficial clinical effect in children and can be indicated in the treatment of refractory vasodilatory shock, after adequate volume resuscitation and when high doses of other vasopressors are not effective.


Assuntos
Hemodinâmica/efeitos dos fármacos , Choque Séptico/tratamento farmacológico , Vasoconstritores/uso terapêutico , Vasodilatadores/uso terapêutico , Vasopressinas/uso terapêutico , Adulto , Animais , Pressão Sanguínea/efeitos dos fármacos , Criança , Estado Terminal , Medicina Baseada em Evidências , Humanos , Infusões Intravenosas , Ensaios Clínicos Controlados Aleatórios como Assunto , Estudos Retrospectivos , Choque Séptico/metabolismo , Choque Séptico/fisiopatologia , Vasoconstrição/fisiologia , Vasodilatação/fisiologia , Vasopressinas/sangue
6.
Indian Pediatr ; 53(11): 987-989, 2016 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-27889726

RESUMO

OBJECTIVE: To describe main indications, doses, length of infusion and side effects related to dexmedetomidine infusion. METHODS: Observational and retrospective study evaluating dexmedetomidine use in pediatric intensive care unit. RESULTS: 77 children received dexmedetomidine infusion longer than 6 hours for mechanical ventilation weaning (32.5%), post- neurosurgery and post-upper airway surgery (24.7%), non-invasive ventilation (13%), refractory tachycardia (6.5%) and other causes (23.3%). After 6 hours of infusion, significant decrease in mean arterial pressure and heart rate was observed in all groups. Six children (8%) required withdrawal of drug because of possible side effects: hypotension, bradycardia and somnolence. CONCLUSION: Dexmedetomidine may be used as sedative in critically ill children without much side effects.


Assuntos
Dexmedetomidina , Hipnóticos e Sedativos , Adolescente , Pressão Sanguínea/efeitos dos fármacos , Brasil , Criança , Pré-Escolar , Estado Terminal , Dexmedetomidina/administração & dosagem , Dexmedetomidina/efeitos adversos , Dexmedetomidina/uso terapêutico , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/efeitos adversos , Hipnóticos e Sedativos/uso terapêutico , Lactente , Infusões Intravenosas , Unidades de Terapia Intensiva Pediátrica , Estudos Retrospectivos , Desmame do Respirador/métodos
7.
Intensive Care Med ; 35(2): 355-9, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19132338

RESUMO

OBJECTIVE: To assess the safety of low-dose vasopressin infusion in critically ill children requiring prolonged mechanical ventilation (MV) at risk of developing sedation/analgesia-related hypotension. METHOD: Randomized pilot safety study in children expected to require MV for at least 3 days. Children received either vasopressin (0.0005 U/kg/min) or sodium chloride (0.9%) infusion for a period of 48 h. Haemodynamic variables, urine output and serum electrolytes were closely monitored and analyzed. RESULTS: Twelve children in each group had similar baseline characteristics. Vasopressin infusion was associated with an 8 mmol/L fall in serum sodium concentration (p < 0.01) and with higher incidence of hyponatraemia (8 vs. 66%, p < 0.01). In normotensive children, low-dose vasopressin also induced a reversible decrease in urine output, and acutely increased blood pressure (p < 0.01). After stopping the vasopressin there was rebound hypotension (p < 0.01). CONCLUSION: Low-dose vasopressin infusion in haemodynamically stable, but critically ill, children is associated with reduction in urine output and decreased serum sodium level, yielding a high incidence of hyponatraemia. We conclude that these effects limit further study of prophylactic vasopressin for sedation-related hypotension in a randomized controlled trial.


Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Hipotensão/tratamento farmacológico , Vasoconstritores/uso terapêutico , Estado Terminal , Esquema de Medicação , Feminino , Humanos , Hiponatremia/sangue , Hipotensão/epidemiologia , Lactente , Recém-Nascido , Masculino , Projetos Piloto , Respiração Artificial , Insuficiência Respiratória/epidemiologia , Insuficiência Respiratória/terapia , Cloreto de Sódio/sangue , Vasoconstritores/administração & dosagem
8.
J. pediatr. (Rio J.) ; J. pediatr. (Rio J.);83(5,supl): S137-S145, Nov. 2007.
Artigo em Inglês, Português | LILACS | ID: lil-470325

RESUMO

OBJETIVO: A vasopressina é um hormônio neuropeptídico utilizado clinicamente há mais de 50 anos, com papel importante na homeostase circulatória e na regulação da osmolalidade sérica. Seu papel no tratamento do choque vem recebendo ênfase recentemente. Foram revisadas a fisiologia deste neuro-hormônio e as evidências disponíveis para sua utilização no contexto de choque com vasodilatação na criança. FONTES DOS DADOS: MEDLINE, usando os termos vasopressin, vasodilation, shock, septic shock, e sinônimos e termos relacionados, além de publicações clássicas referentes ao tema, sendo escolhidas as mais representativas. SÍNTESE DOS DADOS: A vasopressina é sintetizada na neuro-hipófise e liberada em resposta à diminuição da volemia ou ao aumento da osmolalidade plasmática. A ação da vasopressina dá-se pela ativação de vários receptores acoplados à proteína G, os quais são classificados, de acordo com sua localização e rotas de transmissão intracelular, em receptores V1 (ou V1b), V2 e V3 (ou V1b) e por receptores de ocitocina. A função central da vasopressina é causar vasoconstrição, embora, em determinados órgãos, possa promover vasodilatação seletiva. Diversos estudos clínicos em adultos e crianças apontam efeitos benéficos e seguros da vasopressina no tratamento do choque com vasodilatação por diversas causas. CONCLUSÃO: As evidências são restritas, os estudos na maioria são retrospectivos e com número reduzido de pacientes, mas já há uma experiência bastante significativa no que diz respeito a seu uso em pediatria. A vasopressina possui um efeito clinico benéfico na criança e pode ser indicada no tratamento do choque refratário com vasodilatação, depois de adequada reposição volêmica e quando altas doses de outros vasopressores não foram eficazes.


OBJECTIVE:Vasopressin is a neuropeptide hormone which has been used clinically for more than 50 years and plays a major role in circulatory homeostasis and in the regulation of serum osmolality. Recent work has emphasized its role in the treatment of septic shock. This paper reviews the physiology of this neurohormone and the available evidence in favor of its use as a vasodilator for children in shock. SOURCES: MEDLINE, using the terms vasopressin, vasodilation, shock and septic shock, plus synonyms and related terms. Classic publications on the topic were also reviewed and selected depending on their relevance to the study objectives. SUMMARY OF THE FINDINGS: Vasopressin is synthesized in the neurohypophysis and released in response to a decrease in plasma volume or an increase in serum osmolality. The action of vasopressin is mediated by the activation of oxytocin receptors and of several G protein-coupled receptors, which are classified according to their location and intracellular transmission routes as V1 receptors (or V1b), V2 and V3 receptors (or V1b). The main role of vasopressin is to induce vasoconstriction. However, in certain organs, it can also induce selective vasodilation. Several clinical studies in adults and children have reported that the effects of vasopressin for the treatment of vasodilatory septic shock, due to a variety of causes, are both beneficial and safe. CONCLUSIONS: The evidence is restricted. Most studies are retrospective and include a small number of patients. Nevertheless, there is significant experience concerning the use of vasopressin in Pediatrics. Vasopressin has a beneficial clinical effect in children and can be indicated in the treatment of refractory vasodilatory shock, after adequate volume resuscitation and when high doses of other vasopressors are not effective.


Assuntos
Adulto , Animais , Criança , Humanos , Hemodinâmica/efeitos dos fármacos , Choque Séptico/tratamento farmacológico , Vasoconstritores/uso terapêutico , Vasodilatadores/uso terapêutico , Vasopressinas/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Estado Terminal , Medicina Baseada em Evidências , Infusões Intravenosas , Ensaios Clínicos Controlados Aleatórios como Assunto , Estudos Retrospectivos , Choque Séptico/metabolismo , Choque Séptico/fisiopatologia , Vasoconstrição/fisiologia , Vasodilatação/fisiologia , Vasopressinas/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA